AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma - LARVOL DELTA

Successful Treatment of Severe Generalized Pustular Psoriasis with Vunakizumab: A Case Report (AAD 2026) - "This case demonstrates that Vunakizumab can rapidly and effectively control both cutaneous and systemic manifestations of severe GPP. The favorable safety profile and significant clinical improvement support its potential as a therapeutic option for GPP."

Case report • Clinical • Cardiovascular • Dermatology • Diabetes • Dyslipidemia • Genetic Disorders • Hepatology • Hypertension • Immunology • Infectious Disease • Inflammation • Liver Failure • Metabolic Disorders • Obesity • Psoriasis • Pustular Psoriasis • Type 2 Diabetes Mellitus • IL17A

Vunakizumab and Acitretin Combination Therapy for Refractory Generalized Pustular Psoriasis in the Elderly: A Case Report and Literature Review (AAD 2026) - "We report a case of refractory GPP in an elderly patient. Based on the findings from this review, acitretin emerges as an effective and safe option for combination therapy, specifically when used with vunakizumab. Besides IL-36R inhibitors, this study underscores the potential of combination therapy involving biologics and acitretin as an alternative approach for GPP management."

Case report • Clinical • Combination therapy • Review • Dermatology • Immunology • Inflammation • Psoriasis • Pustular Psoriasis • IL17A

Vunakizumab Achieve Complete Remission of Severe Plaque Psoriasis in a 25-Year-Old Male with HIV Infection: A Case Report (AAD 2026) - "No treatment-related adverse events occurred during the treatment period, and the HIV infection did not worsen. Conclusion Vunakizumab led to PASI 100 in a patient with severe plaque psoriasis and HIV co-infection within eight weeks, while maintaining HIV stability and a favorable safety profile.As HIV-positive patients are often excluded from trials, real-world evidence like this case backs vunakizumab as a feasible, effective choice for this refractory group."

Case report • Clinical • Dermatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Psoriasis • CD4 • IL17A

Vunakizumab for Moderate-to-Severe Psoriasis with CARD14 Mutations: A Report of Two Cases (AAD 2026) - "Prior biologic therapies (secukinumab, risankizumab, guselkumab, and ixekizumab) had shown limited efficacy. Conclusion Vunakizumab effectively ameliorates cutaneous lesions and joint pain in psoriasis patients with concurrent CARD14 mutations. While interindividual variability in response was observed between the father and son, our findings collectively validate Vunakizumab as a promising therapeutic option for psoriasis patients with complex genetic profiles."

Clinical • Dermatology • Dermatopathology • Immunology • Inflammatory Arthritis • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies

VIVA-TAK: Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis (clinicaltrials.gov) - P4 | N=180 | Not yet recruiting | Sponsor: Chinese SLE Treatment And Research Group

New P4 trial • Vasculitis • CRP • IL17A

Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): protocol for a multicentre, randomised controlled trial. (PubMed, BMJ Open) - P=N/A | "Research results will be published in peer-reviewed journals. ChiCTR2500101031; https://www.chictr.org.cn/showproj.html?proj=264789."

Journal • Immunology • Osteoarthritis • Pain • Rheumatology • IL17A

Predictors of Efficacy Maintenance After Vunakizumab Discontinuation in Patients With Moderate-to-Severe Plaque Psoriasis: A Post Hoc Analysis of a Randomized Controlled Trial. (PubMed, Int J Dermatol) - P3 | "PASI 90 and PASI 100 maintenance rates are 72.5% and 44.7% after 20 weeks of vunakizumab discontinuation in patients with moderate-to-severe plaque psoriasis. BMI, treatment interruption, and duration of psoriasis predict a lower possibility of efficacy maintenance after vunakizumab discontinuation."

Journal • Retrospective data • Dermatology • Immunology • Psoriasis

Efficacy and Safety of an IL-1 Inhibitor in the Perioperative Period of Patients Undergoing Tophus Resection: A Single-Center, Prospective, Randomized, Positive-Controlled Study (ChiCTR) - P4 | N=54 | Not yet recruiting | Sponsor: The Fifth Hospital of Xi'an; The Fifth Hospital of Xi'an

New P4 trial • Immunology • Inflammatory Arthritis • Rheumatology

Vunakizumab in patients with active psoriatic arthritis: a multicentre, randomized, double-blind, placebo-controlled, phase 2 study. (PubMed, Rheumatology (Oxford)) - P2 | "Vunakizumab demonstrated superior efficacy to placebo and was well tolerated with an acceptable safety profile in patients with active PsA. The findings support proceeding to a phase 3 study."

Clinical • Journal • P2 data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): a Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial (ChiCTR) - P=N/A | N=150 | Recruiting | Sponsor: Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Osteoarthritis • Pain • Rheumatology

Impact of treatment interruption on the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: a post-hoc analysis of a phase 3 trial. (PubMed, Front Immunol) - P3 | "The incidence of overall adverse events was similar between the two groups. Interrupted vunakizumab treatment reduced the clinical response and quality of life in patients with moderate-to-severe plaque psoriasis."

Clinical • Journal • P3 data • Retrospective data • Dermatology • Immunology • Psoriasis • IL17A

Vunakizumab Combined With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and Dyslipidemia (clinicaltrials.gov) - P4 | N=40 | Not yet recruiting | Sponsor: Xiangya Hospital of Central South University

New P4 trial • Dermatology • Dyslipidemia • Immunology • Metabolic Disorders • Psoriasis

Safety profile of vunakizumab in elderly patients with moderate-to-severe plaque psoriasis: a post-hoc analysis. (PubMed, Front Med (Lausanne)) - P3 | "Patient-reported outcomes (PROs) at certain time points during 52 weeks were better in the vunakizumab group than in the placebo group. Vunakizumab is safe and effective in elderly patients with moderate-to-severe plaque psoriasis."

Journal • Retrospective data • Atopic Dermatitis • Dermatology • Dyslipidemia • Hypertriglyceridemia • Immunology • Infectious Disease • Psoriasis • Respiratory Diseases

Efficacy and safety of vunakizumab in moderate-to-severe plaque psoriasis patients with different body mass index: a post hoc analysis based on a phase III trial. (PubMed, Front Pharmacol) - P3 | "The incidences of any adverse events and most specific adverse events did not differ among the groups. A lower BMI is associated with a greater treatment response and quality of life in moderate-to-severe plaque psoriasis patients receiving vunakizumab."

Journal • P3 data • Retrospective data • Dermatology • Immunology • Psoriasis

Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis who have a history of systemic therapies: a post hoc analysis of a phase III trial. (PubMed, Int Immunopharmacol) - P3 | "Vunakizumab has better efficacy than placebo with satisfactory safety profiles in patients with moderate-to-severe plaque psoriasis who have a history of systemic therapies."

Journal • P3 data • Retrospective data • Dermatology • Immunology • Psoriasis

Efficacy and safety of vunakizumab between super responders and non-super responders of patients with moderate-to-severe plaque psoriasis: a post-hoc exploratory analysis of a phase III trial. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - P3 | "The incidence of any adverse events was not different between super responders and non-super responders (all P > 0.05). After vunakizumab treatment, super responder status is associated with better treatment response and PROs in patients with moderate-to-severe plaque psoriasis, while the safety is not affected by this status."

Journal • P3 data • Retrospective data • Dermatology • Immunology • Psoriasis

Early Response to Vunakizumab at Week 2 Predicts Favourable Long-Term Efficacy in Patients With Moderate-To-Severe Plaque Psoriasis: A Post Hoc Analysis of a Phase III, Randomised Controlled Trial. (PubMed, Immunology) - P3 | "Patients with moderate-to-severe plaque psoriasis receiving vunakizumab show a favourable clinical response, regardless of achieving early response or not. Particularly, patients with early response at Week 2 are significantly more likely to achieve better long-term treatment outcomes."

Journal • P3 data • Retrospective data • Dermatology • Immunology • Psoriasis

Efficacy and Safety of Biologics to Treat Adults With Active Radiographic Axial Spondyloarthritis: Systematic Review and Bayesian Network Meta-Analysis (ISPOR-EU 2025) - "OBJECTIVES: To compare efficacy and safety of IL-17 inhibitors in the treatment of adults with active radiographic axial spondyloarthritis (r-AxSpA) over a 16-week period using network meta-analysis (NMA). We conducted systematic literature search in PubMed and Embase in November 2024 to retrieve publications with results of randomized controlled trials (RCTs) evaluating efficacy and safety of IL-17 inhibitors (netakimab, secukinumab, ixekizumab, bimekizumab, brodalumab, xeligekimab, vunakizumab) in adults with active r-AxSpA... Netakimab showed the highest relative efficacy among available IL-17 inhibitors used to treat adults with active r-AxSpA over 16-week horizon and demonstrated a favorable safety profile."

Retrospective data • Review • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A

Adebrelimab combined with vunakizumab for first-line maintenance treatment of extensive-stage small cell lung cancer: A prospective, single-center, single-arm clinical study (ChiCTR) - P4 | N=43 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Nanjing Medical University; The First Affiliated Hospital of Nanjing Medical University

New P4 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Efficacy and Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis by Cigarette Smoking Status: A Post Hoc Analysis of a Randomized, Double-blind, Phase 2/3 Study (ACR Convergence 2025) - P2/3 | "Vunakizumab 120 mg showed significant efficacy and favorable safety in patients with active AS, regardless of cigarette smoking status."

Clinical • P2/3 data • Retrospective data • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A

Efficacy of Vunakizumab in Reducing Pain in Ankylosing Spondylitis: A Post-Hoc Analysis of a Phase 2/3 Clinical Trial (ACR Convergence 2025) - "Vunakizumab provided statistically significant and clinically meaningful reductions in pain outcomes in patients with active AS. Importantly, patients who switched from placebo to vunakizumab at week 16 experienced rapid pain improvement, supporting vunakizumab as an effective treatment strategy for managing pain in AS."

Clinical • P2/3 data • Retrospective data • Ankylosing Spondylitis • Back Pain • Immunology • Inflammation • Inflammatory Arthritis • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Rheumatology • Seronegative Spondyloarthropathies • IL17A

Efficacy And Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis Stratified by Disease Course: A Post-hoc Analysis of a Randomized, Double-Blind, Phase 2/3 Trial (ACR Convergence 2025) - P2/3 | "Vunakizumab 120 mg showed improved efficacy with a manageable safety profile in patients with active AS, irrespective of DC."

Clinical • P2/3 data • Retrospective data • Ankylosing Spondylitis • Immunology • Infectious Disease • Inflammatory Arthritis • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A

Vunakizumab for Treatment of Acrodermatitis Continua of Hallopeau: A Case Report and Literature Review. (PubMed, Psoriasis (Auckl)) - "Emerging evidence indicates that elevated IL-17 levels modulate keratinocyte proliferation and immune cell infiltration, contributing to ACH pathogenesis and representing a promising therapeutic target. Herein, we presented a case of ACH successfully treated with vunakizumab, China's first self-developed anti-IL-17A monoclonal antibody, and reviewed publications reporting IL-17 targeted therapies for ACH, highlighting the potential benefit of IL-17 targeted therapy in ACH management."

Journal • Dermatitis • Dermatology • Immunology • Psoriasis • Pustular Psoriasis • IL17A

Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis across different regions of China: a post-hoc exploratory analysis of a phase III, randomized controlled trial. (PubMed, J Dermatolog Treat) - P3 | "The incidence of adverse events was 80.5%, 90.1%, and 90.1% in the North, Central, and South China groups, respectively. The efficacy and safety of vunakizumab are not affected by different regions of China in patients with moderate-to-severe plaque psoriasis."

Clinical • Journal • P3 data • Retrospective data • Dermatology • Immunology • Psoriasis • IL17A

Efficacy and Safety of Vunakizumab in Psoriasis Patients with Prior IL-17 Inhibitor Failure: A Retrospective Study from China (EADV 2025) - "Vunakizumab has demonstrated favorable effectiveness and safety in patients with secukinumab or ixekizumab therapy failures."

Retrospective data • Dermatology • Immunology • Psoriasis • IL17A • IL23A • TNFA